Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.3900 (-3.75%) ($5.1900 - $5.7200) on Tue. Oct. 20, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.9% (three month average) | RSI | 33 | Latest Price | $5.3900(-3.75%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -10.3% a day on average for past five trading days. | Weekly Trend | ADAP declines -10.4% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) UNG(17%) XLRE(17%) XLP(16%) IFRA(13%) XRT(13%) | Factors Impacting ADAP price | ADAP will decline at least -2.95% in a week (0% probabilities). IPO(-19%) FXI(-15%) ARKG(-15%) TAN(-14%) CEMB(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.95% (StdDev 5.9%) | Hourly BBV | 0 () | Intraday Trend | -4.1% | | | |
|
1 - 5 Day Possible Target | $-14.57(-370.32%) | Resistance Level | $7.77 | 5 Day Moving Average | $6.63(-18.7%) | 10 Day Moving Average | $7.51(-28.23%) | 20 Day Moving Average | $7.77(-30.63%) | To recent high | -50% | To recent low | 0% | Market Cap | $833m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |